HDAC9 and breast cancer: Considering the role of circadian factors in breast cancer tumorogenesis and the potential HDAC inhibiting function, we tested the hypothesis that valeric acid could provide therapeutic benefits against human breast cancer through epigenetic modifications, including DNA methylation and histone deacetylation in the current study.